Published in J Neurovirol on December 16, 2015
Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia (2010) 18.28
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology (2011) 4.63
PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology (2009) 3.37
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol (2009) 3.26
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology (2012) 1.63
Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology (2006) 1.63
Recommendation for a definition of acute symptomatic seizure. Epilepsia (2009) 1.62
Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol (2005) 1.43
Partial cortical deafferentation promotes development of paroxysmal activity. Cereb Cortex (2003) 1.28
Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol (2003) 1.27
Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol (2012) 1.24
Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol (2009) 1.19
Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology (2006) 1.19
Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology (2012) 1.09
Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS (2001) 1.07
Increased propensity to seizures after chronic cortical deafferentation in vivo. J Neurophysiol (2005) 1.04
Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol (2015) 0.99
Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol (2011) 0.97
Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J (2004) 0.94
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk. Mult Scler Relat Disord (2015) 0.91
Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis (2013) 0.90
Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry (2003) 0.89
Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. AIDS (2006) 0.88
Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol (2015) 0.87
Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS (1999) 0.87
Safe Treatment of Seizures in the Setting of HIV/AIDS. Curr Treat Options Neurol (2013) 0.86
Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med (1998) 0.85
Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther (2011) 0.85
Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol (2014) 0.85
New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol (2005) 0.84
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2014) 0.84
Preparing undercut model of posttraumatic epileptogenesis in rodents. J Vis Exp (2011) 0.83
Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol (2010) 0.82
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology (2012) 0.78